摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-氯-2,3-丁二酮 | 5559-62-6

中文名称
1-氯-2,3-丁二酮
中文别名
1-氯丁烷-2,3-二酮;2-三氯甲基-4(3H)-喹唑啉酮
英文名称
1-chloro-2,3-dioxo-butane
英文别名
1-chlorobutane-2,3-dione;1-chloro-butane-2,3-dione;1-Chlor-butan-2,3-dion;Chlordiacetyl;1-chloro-2,3-butanedione
1-氯-2,3-丁二酮化学式
CAS
5559-62-6
化学式
C4H5ClO2
mdl
MFCD18806712
分子量
120.535
InChiKey
AHPSZWVDPABXPI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    56 °C(Press: 15 Torr)
  • 密度:
    1.2620 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    7
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    34.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2914700090

SDS

SDS:c5a74b3d5629d15d99fce657094ff7e6
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    US2733268
    摘要:
    公开号:
  • 作为产物:
    描述:
    2,3-丁二酮磺酰氯 作用下, 以 为溶剂, 以51.5%的产率得到1-氯-2,3-丁二酮
    参考文献:
    名称:
    Process for producing 2-(2-aminothiazol-4-yl)glyoxylic acid derivative
    摘要:
    这项发明涉及一种用于生产2-(2-氨基噻唑-4-基)甘氨酸衍生物或其盐的新型工艺,该衍生物在生产头孢菌素抗生素中具有用途,并涉及用于该衍生物和盐的中间体以及生产中间体的工艺。
    公开号:
    US04563534A1
点击查看最新优质反应信息

文献信息

  • Substituted hydantoins
    申请人:Chu Xin-Jie
    公开号:US20060041146A1
    公开(公告)日:2006-02-23
    The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.
    本发明涉及一类化合物,其结构式如下: 这些化合物在治疗由MEK过度活跃引起的疾病方面具有用途。因此,这些化合物在治疗诸如癌症、认知和CNS疾病以及炎症/自身免疫疾病等疾病方面是有用的。
  • Preparation and Biological Activity of 2-(4-(Thiazol-2-yl)phenyl)propionic Acid Derivatives Inhibiting Cyclooxygenase.
    作者:Youichiro NAITO、Tomokazu GOTO、Fumihiko AKAHOSHI、Shiniciro ONO、Haruko YOSHITOMI、Tadashi OKANO、Naoki SUGIYAMA、Shunichi ABE、Syuichi HANADA、Mitsuru HIRATA、Masahiro WATANABE、Chikara FUKAYA、Kazumasa YOKOYAMA、Toshio FUJITA
    DOI:10.1248/cpb.39.2323
    日期:——
    A series of 2-[4-(thiazol-2-yl)phenyl]propionic acids substituted at various positions were prepared by the reaction of diethyl 2-methyl-2-(4-thiocarbamoylphenyl)malonates with alpha-bromoaldehyde diethyl acetals or alpha-haloketones followed by hydrolysis of esters. The inhibition of prostaglandin H synthetase (cyclooxygenase) was assayed by use of an enzyme preparation from guinea pig polymorphonuclear
    通过使2-甲基-2-(4-硫代氨基甲酰基苯基)丙二酸二乙酯与α-溴醛二乙缩醛或α反应制备一系列在各个位置取代的2- [4-(噻唑-2-基)苯基]丙酸。 -卤代酮,然后酯水解。通过使用来自豚鼠多形核白细胞的酶制剂测定前列腺素H合成酶(环加氧酶)的抑制作用。这些化合物的结构活性关系的研究表明,苯环3位(R1)处的卤素和噻唑环4位(R2)和/或5位(R3)处的甲基被卤素取代是有利的抑制活性。在R2位带有大的烷基或极性官能团的化合物是弱抑制剂。测试了有效的环氧合酶抑制剂减轻角叉菜胶诱导的大鼠爪炎症的能力。这些衍生物由于对环加氧酶的强抑制作用而具有很强的抗炎活性,除了一些例外,包括那些在R1处带有硫代甲基的衍生物。
  • [EN] (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR<br/>[FR] DERIVES HETEROCYCLIQUES-(INDOL-3-YL) COMME AGONISTES DU RECEPTEUR DU CANNABINOIDE CB1
    申请人:AKZO NOBEL NV
    公开号:WO2005089754A1
    公开(公告)日:2005-09-29
    The invention relates to (indol-3-yl)-heterocycle derivatives having general Formula (I) wherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CR; R is H or (C1-4)alkyl; or R, when present in X2 or X3, may form together with R3 a 5-8 membered ring; R1 is a 5-8 mem­bered saturated carbocyclic ring, optionally containing a heteroatom selected from O and S; R2 is H, CH3 or CH2-CH3; or R2 is joined together with R7 to form a 6-mem­bered ring, optionally containing a heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring; R3 and R4 are independent­ly H, (C1-6)alkyl or (C3-7)cycloalkyl, the alkyl groups being optionally substituted with OH, (C1-4)alkyloxy, (C1-4)alkylthio, (C1-4)alkylsulfonyl, CN or halogen; or R3 together with R4 and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally sub­stituted with OH, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy- (C1-4)alkyl, or halogen; or R3 together with R5 forms a 4-8 membered ring optionally containing a further hetero­atom selected from O and S, and which is optionally substituted with OH, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy- (C1-4)alkyl, or halogen; or R3 together with R, when present in X2 or X3, forms a 5-8 membered ring; R5 is H or (C1-4)alkyl; or R5 together with R3 forms a 4-8 membered ring optionally containing a further heteroatom select­ed from O and S, and which is optionally substituted with OH, (C1-4)alkyl, (C1-4)alkyl­oxy, (C1-4) alkyloxy- (C1-4)alkyl, or halogen; R5' is H or (C1-4)alkyl; R6 represents 1-3 substituents independently selected from H, (C1-4 alkyl, (C1-4) alkyloxy, CN and halogen; R7 is H, (C1-4)alkyl, (C1-4)alkyloxy, CN or halogen; or R7 is joined together with R2 to form a 6-membered ring, optionally containing a further heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring; or a pharmaceutically acceptable salt thereof, as agonists of the cannabinoid CB1 receptor, which can be used in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.
    该发明涉及具有一般式(I)的(吲哚-3-基)-杂环衍生物,其中A代表一个5-成员芳香杂环环,其中X1、X2和X3分别选自N、O、S和CR;R为H或(C1-4)烷基;或者R,在X2或X3中时,可以与R3一起形成一个5-8成员环;R1是一个5-8成员饱和碳环,可选地含有从O和S中选取的杂原子;R2为H、CH3或CH2-CH3;或者R2与R7结合形成一个6-成员环,可选地含有从O和S中选取的杂原子,并且该杂原子与吲哚环的7-位置相结合;R3和R4独立地为H、(C1-6)烷基或(C3-7)环烷基,烷基基团可选地用OH、(C1-4)烷氧基、(C1-4)烷基硫醚、(C1-4)烷基磺酰基、CN或卤素取代;或者R3与R4和它们结合的N形成一个4-8成员环,可选地含有从O和S中选取的进一步杂原子,并且可选地用OH、(C1-4)烷基、(C1-4)烷氧基、(C1-4)烷氧基-(C1-4)烷基或卤素取代;或者R3与R5形成一个4-8成员环,可选地含有从O和S中选取的进一步杂原子,并且可选地用OH、(C1-4)烷基、(C1-4)烷氧基、(C1-4)烷氧基-(C1-4)烷基或卤素取代;或者R3与R,在X2或X3中时,形成一个5-8成员环;R5为H或(C1-4)烷基;或者R5与R3一起形成一个4-8成员环,可选地含有从O和S中选取的进一步杂原子,并且可选地用OH、(C1-4)烷基、(C1-4)烷氧基、(C1-4)烷氧基-(C1-4)烷基或卤素取代;R5'为H或(C1-4)烷基;R6代表独立选择的1-3个取代基,选自H、(C1-4)烷基、(C1-4)烷氧基、CN和卤素;R7为H、(C1-4)烷基、(C1-4)烷氧基、CN或卤素;或者R7与R2结合形成一个6-成员环,可选地含有从O和S中选取的进一步杂原子,并且该杂原子与吲哚环的7-位置相结合;或其药学上可接受的盐,作为大麻素CB1受体的激动剂,可用于治疗疼痛,例如围手术期疼痛、慢性疼痛、神经痛、癌症疼痛以及与多发性硬化相关的疼痛和痉挛。
  • Argyranthemum plant named ‘G15104’
    申请人:Palmer Irene E.
    公开号:USPP029843P2
    公开(公告)日:2018-11-13
    A new and distinct cultivar of Argyranthemum plant named ‘G15104’, characterized by its upright and somewhat outwardly spreading plant habit; freely branching habit; dense and bushy appearance; freely flowering habit; large single-type inflorescences with creamy yellow-colored ray florets and yellow orange-colored disc florets; and good garden performance.
    一种新的独特的Marguerite花卉品种,命名为“ G15104”,其特征是:植株姿态直立,稍微向外扩展;自由分枝;浓密且丛状;自由开花;大型单朵花序,具有奶油黄色的舌状花和黄橙色的管状花;良好的花园表现。
  • (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor
    申请人:Adam-Worrall Julia
    公开号:US20070142446A1
    公开(公告)日:2007-06-21
    Disclosed herein are indole derivatives of the formula (I) wherein each of the substitutents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the indole derivatives and use of the derivatives for the treatment of pain.
    本文揭示了公式(I)的吲哚衍生物,其中每个取代基的定义如规范和要求所述。还揭示了含有这些吲哚衍生物的药物组合物,并且这些衍生物可用于治疗疼痛。
查看更多